PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32859280-0 2021 Prognostic Value of EGFR Expression for Patients with Stage III Colorectal Cancer Receiving Fluoropyrimidine Metronomic Maintenance Therapy After Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy. 2-fluoropyrimidine 92-108 epidermal growth factor receptor Homo sapiens 20-24 26475168-0 2015 Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method. 2-fluoropyrimidine 120-136 epidermal growth factor receptor Homo sapiens 62-66 26475168-10 2015 Recent studies showed that the mutations in EGFR is associated with high expression of dihydropyrimidine dehydrogenase, which is an inactivating and rate-limiting enzyme for fluoropyrimidine, and suggested that the combination of chemotherapy with fluoropyrimidine and EGFR-targeting agents is effective against EGFR-overexpressing gastric tumors, while ANXA3 overexpression confers resistance to tyrosine kinase inhibitors targeting the EGFR pathway. 2-fluoropyrimidine 174-190 epidermal growth factor receptor Homo sapiens 44-48 26475168-10 2015 Recent studies showed that the mutations in EGFR is associated with high expression of dihydropyrimidine dehydrogenase, which is an inactivating and rate-limiting enzyme for fluoropyrimidine, and suggested that the combination of chemotherapy with fluoropyrimidine and EGFR-targeting agents is effective against EGFR-overexpressing gastric tumors, while ANXA3 overexpression confers resistance to tyrosine kinase inhibitors targeting the EGFR pathway. 2-fluoropyrimidine 174-190 epidermal growth factor receptor Homo sapiens 269-273 26475168-10 2015 Recent studies showed that the mutations in EGFR is associated with high expression of dihydropyrimidine dehydrogenase, which is an inactivating and rate-limiting enzyme for fluoropyrimidine, and suggested that the combination of chemotherapy with fluoropyrimidine and EGFR-targeting agents is effective against EGFR-overexpressing gastric tumors, while ANXA3 overexpression confers resistance to tyrosine kinase inhibitors targeting the EGFR pathway. 2-fluoropyrimidine 174-190 epidermal growth factor receptor Homo sapiens 269-273 26475168-10 2015 Recent studies showed that the mutations in EGFR is associated with high expression of dihydropyrimidine dehydrogenase, which is an inactivating and rate-limiting enzyme for fluoropyrimidine, and suggested that the combination of chemotherapy with fluoropyrimidine and EGFR-targeting agents is effective against EGFR-overexpressing gastric tumors, while ANXA3 overexpression confers resistance to tyrosine kinase inhibitors targeting the EGFR pathway. 2-fluoropyrimidine 174-190 epidermal growth factor receptor Homo sapiens 269-273 26475168-10 2015 Recent studies showed that the mutations in EGFR is associated with high expression of dihydropyrimidine dehydrogenase, which is an inactivating and rate-limiting enzyme for fluoropyrimidine, and suggested that the combination of chemotherapy with fluoropyrimidine and EGFR-targeting agents is effective against EGFR-overexpressing gastric tumors, while ANXA3 overexpression confers resistance to tyrosine kinase inhibitors targeting the EGFR pathway. 2-fluoropyrimidine 248-264 epidermal growth factor receptor Homo sapiens 44-48 26475168-10 2015 Recent studies showed that the mutations in EGFR is associated with high expression of dihydropyrimidine dehydrogenase, which is an inactivating and rate-limiting enzyme for fluoropyrimidine, and suggested that the combination of chemotherapy with fluoropyrimidine and EGFR-targeting agents is effective against EGFR-overexpressing gastric tumors, while ANXA3 overexpression confers resistance to tyrosine kinase inhibitors targeting the EGFR pathway. 2-fluoropyrimidine 248-264 epidermal growth factor receptor Homo sapiens 269-273 26475168-10 2015 Recent studies showed that the mutations in EGFR is associated with high expression of dihydropyrimidine dehydrogenase, which is an inactivating and rate-limiting enzyme for fluoropyrimidine, and suggested that the combination of chemotherapy with fluoropyrimidine and EGFR-targeting agents is effective against EGFR-overexpressing gastric tumors, while ANXA3 overexpression confers resistance to tyrosine kinase inhibitors targeting the EGFR pathway. 2-fluoropyrimidine 248-264 epidermal growth factor receptor Homo sapiens 269-273 26475168-10 2015 Recent studies showed that the mutations in EGFR is associated with high expression of dihydropyrimidine dehydrogenase, which is an inactivating and rate-limiting enzyme for fluoropyrimidine, and suggested that the combination of chemotherapy with fluoropyrimidine and EGFR-targeting agents is effective against EGFR-overexpressing gastric tumors, while ANXA3 overexpression confers resistance to tyrosine kinase inhibitors targeting the EGFR pathway. 2-fluoropyrimidine 248-264 epidermal growth factor receptor Homo sapiens 269-273 25573239-0 2015 Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase-inhibitory fluoropyrimidine in EGFR-mutated lung adenocarcinoma: retrospective and in vitro studies. 2-fluoropyrimidine 98-114 epidermal growth factor receptor Homo sapiens 118-122 25573239-2 2015 We retrospectively compared the efficacy of standard platinum-based chemotherapy with that of combination chemotherapy using vinorelbine (VNR) plus dihydropyrimidine dehydrogenase-inhibitory fluoropyrimidine (DIF) in EGFR-mutated lung adenocarcinomas, and we investigated a potential mechanism by which the combination chemotherapy of VNR + DIF was favorable in the treatment of EGFR-mutated lung adenocarcinoma in vitro. 2-fluoropyrimidine 191-207 epidermal growth factor receptor Homo sapiens 217-221 23816762-9 2013 Recent studies have shown that combination chemotherapy of fluoropyrimidine and EGFR-targeting agents is effective for gastric cancer patients highly expressing EGFR. 2-fluoropyrimidine 59-75 epidermal growth factor receptor Homo sapiens 161-165 23741067-2 2013 EXPERIMENTAL DESIGN: We used Sequenom and Pyrosequencing for high-throughput somatic profiling of the EGFR pathway in 1,976 tumors from patients with advanced colorectal cancer from the COIN trial (oxaliplatin and fluoropyrimidine chemotherapy +- cetuximab). 2-fluoropyrimidine 214-230 epidermal growth factor receptor Homo sapiens 102-106 22949147-1 2012 PURPOSE: Treatment for metastatic colorectal cancer (mCRC) commonly involves a fluoropyrimidine-based chemotherapy regimen such as infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) or fluorouracil, leucovorin, and oxaliplatin, often combined with bevacizumab or an epidermal growth factor receptor monoclonal antibody. 2-fluoropyrimidine 79-95 epidermal growth factor receptor Homo sapiens 277-309 20180626-13 2010 DISCUSSION: Potential reasons for the disappointing results of EGFR inhibition with fluoropyrimidine-based preoperative chemoradiation include a less critical role of repopulation in rectal adenocarcinoma using a non-curative radiation dose; or antagonistic effects on 5FU-based chemoradiation and oxaliplatin, if some cells arrest in G1 or G2-M and fail to pass through S phase. 2-fluoropyrimidine 84-100 epidermal growth factor receptor Homo sapiens 63-67 20435574-6 2010 We found that the fluoropyrimidine down-regulated EGFR expression by 30%, an unexpected finding resulting in a possible reduction in efficacy when cells were subsequently exposed to erlotinib. 2-fluoropyrimidine 18-34 epidermal growth factor receptor Homo sapiens 50-54 18253119-1 2008 There are data suggesting that inhibition of epidermal growth factor receptor (EGFR) tyrosine kinase signalling may reverse resistance to fluoropyrimidine treatment. 2-fluoropyrimidine 138-154 epidermal growth factor receptor Homo sapiens 45-77 18253119-1 2008 There are data suggesting that inhibition of epidermal growth factor receptor (EGFR) tyrosine kinase signalling may reverse resistance to fluoropyrimidine treatment. 2-fluoropyrimidine 138-154 epidermal growth factor receptor Homo sapiens 79-83 19529774-1 2009 BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) has been shown to exert a synergistic antitumor effect when combined with fluoropyrimidine. 2-fluoropyrimidine 156-172 epidermal growth factor receptor Homo sapiens 72-76 19047118-1 2008 PURPOSE: Recently, an objective response rate of 12% was reported in a phase II study of cetuximab in patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC) refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy (IMC-0144). 2-fluoropyrimidine 217-233 epidermal growth factor receptor Homo sapiens 150-154 32859280-1 2021 This study evaluated the survival effects of metronomic maintenance therapy with oral fluoropyrimidine in patients with stage III colorectal cancer (CRC) according to epidermal growth factor receptor (EGFR) expression. 2-fluoropyrimidine 86-102 epidermal growth factor receptor Homo sapiens 167-199 32859280-1 2021 This study evaluated the survival effects of metronomic maintenance therapy with oral fluoropyrimidine in patients with stage III colorectal cancer (CRC) according to epidermal growth factor receptor (EGFR) expression. 2-fluoropyrimidine 86-102 epidermal growth factor receptor Homo sapiens 201-205 28794362-0 2017 Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine. 2-fluoropyrimidine 131-147 epidermal growth factor receptor Homo sapiens 57-89 28794362-2 2017 We describe a case of synchronous duodenal cancer with lung cancer harboring an epidermal growth factor receptor (EGFR) mutation treated with erlotinib and S-1, an oral fluoropyrimidine agent. 2-fluoropyrimidine 169-185 epidermal growth factor receptor Homo sapiens 80-112 28794362-2 2017 We describe a case of synchronous duodenal cancer with lung cancer harboring an epidermal growth factor receptor (EGFR) mutation treated with erlotinib and S-1, an oral fluoropyrimidine agent. 2-fluoropyrimidine 169-185 epidermal growth factor receptor Homo sapiens 114-118